Pharma stock jumps 4% after receiving approval to import cancer treatment drug

1. AstraZeneca Pharma India's stock price rose by 4.75% to Rs. 5,300 on BSE on March 27th after receiving approval for a new drug.

2. The company's market capitalization is Rs. 13,094.5 crore, and its shares were trading at Rs. 5,231.9, up by 2.94% at 12:34 p.m.

3. Over the past year, the company has delivered positive returns of 56.7% and 18.2% in the last six months, but negative returns of 7.3% in 2024.

4. AstraZeneca Pharma India received approval to import Trastuzumab deruxtecan for treating HER2-low breast cancer and HER2-positive gastric cancer.

5. The company's revenue grew by 22.4% YoY to Rs. 306 crore in Q3 FY23–24, but net profit decreased by 44.8% YoY to Rs. 16 crore.

6. Foreign institutional investors (FIIs) hold 2.66% and domestic institutional investors (DIIs) hold 2.76% of the company's shares.

7. Established in 1979, AstraZeneca Pharma India concentrates on the manufacturing, distribution, and marketing of pharmaceutical products.

8. The company specializes in prescription medicines for therapy areas like oncology, biopharmaceuticals, and rare diseases.